STOCK TITAN
  1. Home
  2. News
  3. IONS

Ionis Pharmaceuticals Inc - IONS STOCK NEWS

Welcome to our dedicated news page for Ionis Pharmaceuticals (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ionis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ionis Pharmaceuticals's position in the market.

News
Ionis to hold fourth quarter and full year 2023 financial results webcast
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) will host a live webcast on February 21st at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2023 financial results. The webcast can be accessed at https://ir.ionispharma.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
earnings
-
News
Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases
Rhea-AI Summary
Vect-Horus, a biotechnology company, has entered into a global license agreement with Ionis Pharmaceuticals, Inc. The agreement provides Ionis with an exclusive license for a specified number of targets using Vect-Horus’ platform technology for systemic delivery of RNA-targeted therapeutics that can cross the blood-brain barrier. Vect-Horus will receive a double-digit million-dollar upfront payment, development, regulatory, and commercial milestone payments, and tiered single digit royalties on annual product sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
News
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. announced positive Phase 3 OASIS-HAE study results for donidalorsen in treating hereditary angioedema, meeting primary endpoint with significant reduction in attack rate, favorable safety profile, and plans for FDA and EMA submissions. Donidalorsen targets prekallikrein to interrupt HAE attacks, with plans for independent drug launches and presentations of Phase 3 results at medical congress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
clinical trial
News
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced their 2023 achievements and previewed important milestones for 2024, including U.S. approval of WAINUA™ and QALSODY® for serious diseases, positive Phase 3 trial readouts, and expansion of their late-stage pipeline to nine medicines in Phase 3 trials for 11 potential indications. They also made advances in their technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
none
-
News
Alcyone Therapeutics Announces First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx™ System for Administration of SPINRAZA® (nusinersen)
Rhea-AI Summary
Alcyone Therapeutics Inc. (Alcyone) announced the first patient implanted in the PIERRE pivotal study to evaluate the safety and performance of the ThecaFlex DRx System (ThecaFlex) subcutaneous port and intrathecal catheter system for repeat intrathecal access, cerebrospinal fluid (CSF) aspiration, and delivery of SPINRAZA® (nusinersen) in spinal muscular atrophy (SMA) patients. The ThecaFlex device has the potential to significantly benefit patients with SMA who are being treated with SPINRAZA and are resistant to lumbar punctures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
clinical trial
-
News
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced FDA approval of WAINUA™ (eplontersen) for the treatment of hATTR-PN in adults. WAINUA demonstrated consistent and sustained benefit in halting neuropathy disease progression and improving quality of life. It will be available in the U.S. in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none
News
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) CEO to present company overview at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.94%
Tags
conferences
-
News
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. to exclusively commercialize donidalorsen in Europe for hereditary angioedema (HAE). Ionis will independently bring donidalorsen to U.S. patients if approved, with Phase 3 results expected in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
News
Ionis announces the appointment of Michael Yang to Board of Directors
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has appointed Michael Yang, an experienced biopharmaceutical executive, to its Board of Directors, expanding the total number of members to 10. Mr. Yang has over 20 years of leadership experience in biotech, pharmaceutical, and medical device companies, with significant achievements in launching new platforms, expanding global revenues, and diversifying product lines. His most recent role was as President, CEO, and Board member of ViaCyte, which was acquired by Vertex in 2022. Ionis' CEO, Brett P. Monia, and Board Chairman, Joseph Loscalzo, M.D., Ph.D., expressed excitement about Michael's appointment, highlighting his deep biopharmaceutical leadership experience and strong patient focus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
management
News
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
Rhea-AI Summary
IONIS: Part 1 of HALOS trial for ION582 in Angelman syndrome completes enrollment with positive preliminary findings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock IONS logo
Ionis Pharmaceuticals Inc

Nasdaq:IONS

IONS Rankings

#1084 Ranked by Market Cap
#2013 Ranked by Stock Gains
N/A Ranked by Dividends

IONS Stock Data

6.08B
144.53M
0.86%
100.99%
6.53%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Carlsbad

About IONS

ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.